These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38053051)

  • 1. Competing treatments for migraine: a headache for decision-makers.
    Mistry H; Naghdi S; Underwood M; Duncan C; Madan J; Matharu M
    J Headache Pain; 2023 Dec; 24(1):162. PubMed ID: 38053051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling.
    Mistry H; Naghdi S; Brown A; Rees S; Madan J; Grove A; Khanal S; Duncan C; Matharu M; Cooklin A; Aksentyte A; Davies N; Underwood M
    Health Technol Assess; 2024 Oct; 28(63):1-329. PubMed ID: 39365169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis.
    Naghdi S; Underwood M; Madan J; Brown A; Duncan C; Matharu M; Aksentyte A; Davies N; Rees S; Cooklin A; Grove A; Mistry H
    J Headache Pain; 2023 Dec; 24(1):164. PubMed ID: 38057728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity.
    Griffin E; Shirley G; Lee XY; Awad SF; Tyagi A; Goadsby PJ
    J Headache Pain; 2024 Apr; 25(1):59. PubMed ID: 38637754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
    Pozo-Rosich P; Poveda JL; Crespo C; Martínez M; Rodríguez JM; Irimia P
    J Headache Pain; 2024 Mar; 25(1):40. PubMed ID: 38491460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK.
    Hollier-Hann G; Curry A; Onishchenko K; Akehurst R; Ahmed F; Davies B; Keyzor I
    J Med Econ; 2020 Jan; 23(1):113-123. PubMed ID: 31578100
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK.
    Johnston K; Powell LC; Popoff E; L'Italien GJ; Pawinski R; Ahern A; Large S; Tran T; Jenkins A
    J Med Econ; 2024; 27(1):627-643. PubMed ID: 38590236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.
    Sutcliffe P; Connock M; Pulikottil-Jacob R; Kandala NB; Suri G; Gurung T; Grove A; Shyangdan D; Briscoe S; Maheswaran H; Clarke A
    Health Technol Assess; 2013 Nov; 17(53):1-499, v-vi. PubMed ID: 24280231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective.
    Takeshima T; Sakai F; Wang X; Yamato K; Kojima Y; Zhang Y; Bennison C; Simons MJHG
    Pharmacoeconomics; 2024 Jul; 42(7):811-822. PubMed ID: 38771521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
    Batty AJ; Hansen RN; Bloudek LM; Varon SF; Hayward EJ; Pennington BW; Lipton RB; Sullivan SD
    J Med Econ; 2013 Jul; 16(7):877-87. PubMed ID: 23647483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.
    Lipton RB; Brennan A; Palmer S; Hatswell AJ; Porter JK; Sapra S; Villa G; Shah N; Tepper S; Dodick D
    J Med Econ; 2018 Jul; 21(7):666-675. PubMed ID: 29571276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features.
    Chiang CC; Schwedt TJ; Dumkrieger G; Wang L; Chao CJ; Ouellette HA; Banerjee I; Chen YC; Jones BM; Burke KM; Wang H; Murray AM; Montenegro MM; Stern JI; Whealy M; Kissoon N; Cutrer FM
    Headache; 2024 Oct; 64(9):1094-1108. PubMed ID: 39176658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model.
    Thaliffdeen R; Yu A; Rascati K
    Clin Drug Investig; 2024 Mar; 44(3):209-217. PubMed ID: 38381352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway.
    Hansson-Hedblom A; Axelsson I; Jacobson L; Tedroff J; Borgström F
    J Headache Pain; 2020 Aug; 21(1):99. PubMed ID: 32787820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
    Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
    BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.
    Yu J; Smith KJ; Brixner DI
    CNS Drugs; 2010 Aug; 24(8):695-712. PubMed ID: 20658800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.